Zogenix Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, Calif., September 7, 2010 — Zogenix, Inc. (“Zogenix”) announced today that it has filed a registration statement with the Securities and Exchange Commission (”SEC”) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Zogenix.
Wells Fargo Securities, LLC and Leerink Swann LLC are acting as joint book-running managers for the offering, and Oppenheimer & Co. and Stifel Nicolaus Weisel are acting as co-managers for the offering. This offering will be made only by means of a prospectus. Once available, copies of the prospectus relating to this offering may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by calling toll-free 800-326-5897 or emailing a request to equity.syndicate@wellsfargo.com and from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling toll-free 800-808-7525 or emailing a request to Syndicate@Leerink.com.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Zogenix
Zogenix, Inc., with offices in Emeryville and San Diego, Calif., is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix’s first commercial product, Sumavel™ DosePro™ (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
# # #
CONTACTS:
Catherine O‘Connor | Zogenix, Inc.
858.436.3374 | coconnor@zogenix.com
Historical Information: The press releases are included on this web site for historical purposes only. The information contained in these press releases should be considered accurate only as of the date of the relevant press release. This information may change over time. Visitors to this web site should not assume that the information contained in these press releases remains accurate at a later time. Except as required by law, we undertake no obligation to update, revise or supplement any of the information contained in these press releases.
